The effects of sitagliptin as a DPPIV inhibitor on vascular endothelial and autonomic nerve functions in patients with type II diabetes mellitus. - The effects of sitagliptin as a DPPIV inhibitor on vascular endothelial and autonomic nerve functions in patients with type II diabetes mellitus.

ippon Medical School Department of Medicine Division of Cardiology, Hepatology,Geriatrics and Integrated Medicine0 个研究点目标入组 40 人开始时间: 2010年9月20日最近更新: 2023年10月17日

适应症

试验速览

阶段: 未知
状态: 已完成
发起方
入组人数: 40

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional

入排标准

年龄范围: 20years-old 至 ot applicable（—）
性别: All

入选标准

未提供

排除标准

•1) Type I diabetes mellitus 2) Patients receiving insulin therapy 3) Severe renal dysfunction requiring hemodialysis or peritoneal dialysis 4) Severe hepatopathy/nephropathy or heart disease that may affect the evaluation of drug safety 5) Patients who are deemed to be inappropriate by the investigator or sub-investigators

研究者

发起方

ippon Medical School Department of Medicine Division of Cardiology, Hepatology,Geriatrics and Integrated Medicine

相似试验

已完成

不适用

The effects of vildagliptin as a DPPIV inhibitor on vascular endothelial and myocardial injury in patients with type II diabetes mellitus.Type II diabetes mellitus

JPRN-UMIN000007111ippon Medical School Department of Medicine Division of Cardiology, Hepatology,Geriatrics and Integrated Medicine40

终止

2 期

Sitagliptin in Cystic Fibrosis-Related DiabetesCystic Fibrosis

NCT01257464University of British Columbia3

尚未招募

4 期

Sitagliptin compared to glimepiride on vascular risk factors among patients with type 2 diabetes mellitusType 2 Diabetes Mellitus

SLCTR/2015/022niversity Grants Commission, Sri Lanka

招募中

3 期

Evaluation of the effectiveness of sitagliptin on metabolic factors and liver enzymes

IRCT20191209045671N2Semnan University of Medical Sciences60

已完成

1 期

Effects of sitagliptin, a dipeptidyl peptidase IV (DPP IV) inhibitor, on blood glucose and plasma incretin and insulin responses to small intestinal glucose infusion, in healthy lean and obese subjects, and alone or in combination with metformin in patients with type 2 diabetes mellitus.

ACTRN12608000433303Royal Adelaide Hospital36